Tempest Therapeutics, Inc. (OVAS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Operating expenses:
Research and development	22.5	17.2	14.4	27.8	14.4	18.3	21.6	18.4
General and administrative	12.1	9.8	4.9	17.6	8.7
Loss from operations	-34.6	-27.0	-19.3	45.4	26.9	-50.6	-81.0	-72.0

Other income (expense), net:
Interest expense	-1.6	-1.3
Interest income and other income (expense), net	0.5	0.0	0.1	0.2	0.2	0.0	-0.2	0.0
Total other income (expense), net	-1.1	-1.3	0.1
Provision for income taxes					0.0	0.1	0.2	0.1
Net loss	-35.7	-28.3	-19.2	-44.6	-27.2

Net loss per share of common stock and pre-funded warrants, basic	($3.09)	($7.47)	($41.03)	($3.25)	($17.58)	($1.43)	($2.56)	($2.70)
Net loss per share of common stock and pre-funded warrants, diluted	($3.09)	($7.47)	($41.03)	($3.25)	($17.58)	($1.43)	($2.56)	($2.70)

Weighted-average shares of common stock and pre-funded warrants outstanding, basic	11.5	3.8	0.5	13.7	1.5	35.7	32.1	27.1
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	11.5	3.8	0.5